Table 3.
Table of recruiting trials of importance for DPN pain.
| Sponsor/PI | NCT Number | Study Description | # of Participants | Phase | Intervention | Drug Group |
|---|---|---|---|---|---|---|
| Vrooman et al. | NCT04678895 | R, DB, PC, Crossover Trial | 35 | 2 | Naltrexone Placebo |
Opioid antagonist |
| AstraZeneca | NCT03755934 | R, DB, PC, Dose–Response Study | 111 | 2 | MEDI7352 Placebo |
Fusion protein binding nerve growth factor (NGF) to tumor necrosis factor receptor 2 (TNFR2) |
| Rathmell et al. | NCT05480228 | Prospective, Parallel Group, Multicenter, R, DB, PC | 122 | 2 | NRD135SE.1 Placebo |
Non-opioid molecule with unknown target |
| Basit et al. | NCT05080530 | Non-R, No Masking (Open-Label) | 216 | N/A | Cholecalciferol | Vitamin D analog |
| Vertex Pharmaceuticals | NCT05660538 | R, DB, Active-Controlled, Dose-Ranging, Parallel Design Study | 175 | 2 | VX-548 Pregabalin Placebo |
Selective NaV1.8 sodium channel inhibitor GABA analog |
| Mittendorfer et al. | NCT05145452 | R, DB, Controlled Trial | 60 | N/A | Fish oil-derived n-3 polyunsaturated fatty acids | Lipid-regulating agent |
| Eli Lilly and Co. | NCT05620576 | R, PC Master Protocol | 125 | 2 | LY3857210 Placebo |
P2XY inhibitor |
| Elsharab et al. | NCT05369793 | R, No Masking (Open-Label) | 60 | 3 | Alpha-lipoic acid Roflumilast |
Antioxidant Phosphodiesterase inhibitor |
| Zhao et al. | NCT05507697 | R, Open-Label, Single-Center Trial | 42 | 2 | HUC-MSCs Lipoic acid |
Stem cells |
| Rastogi et al. | NCT05162690 | R, PC, Double Masking Trial | 40 | 3 | Dapagliflozin Placebo |
Sodium-glucose cotransporter 2 (SGLT2) inhibitor |
| Emara et al. | NCT04766450 | R, Open-Label, Controlled Trial | 30 | 4 | Acetyl-cysteine | Anti-oxidant |
| Ameo et al. | NCT05247034 | R, DB, Controlled Trial | 5 | N/A | Cocoa supplement | Anti-inflammatory and anti-oxidant |
| Wang et al. | NCT04457531 | R, Open-Label, Controlled Study | 60 | 1 | LiuWeiLuoBi granule | Anti-inflammatory |
R—randomized; DB—double-blind; PC—placebo-controlled.